July 27, 2017

The three-day conference will take place from Sept. 18 through Sept. 20 at the Marriot Wardman Park in Washington, D.C.

July 20, 2017

Gilead’s hepatitis C treatment Vosevi and Puma Biotechnology’s breast cancer drug Nerlynx both earned Food and Drug Administration approval this week. 

July 19, 2017

The organization has brought onto its board Walgreens VP federal government relations and U.S. public policy Ed Kaleta; Pfizer's regional president North America for rare disease Tolga Tangular; and AstraZeneca’s executive director of access services Blaine Squires. 

July 14, 2017

Tremfya (guselkumab) is the first drug to be approved that selectively blocks a key plaque psoriasis cytokine, the company said.

July 14, 2017

Mike Hotra joins the organization as VP of its public affairs team, and Ken McKay is the advocacy organization’s new VP state government affairs. 

July 12, 2017
The drug had previously been granted breakthrough therapy designation and accelerated approval.
July 7, 2017

Diplomat Specialty Infusion Group’s nutrition division ThriveRx is celebrating 10 years of supporting parenteral and enteral nutrition patients with a website redesign and the rebrand of its Maximize Health program. 

July 6, 2017
Walmart Specialty Pharmacy provides such services as prior authorization, identifying the lowest possible price for medications and creating a personal care plan for patients. 
June 30, 2017

Along with the new indication, the Food and Drug Administration DA approved a next-generation sequencing-based test to identify the RAS mutation status of a patient’s tumor, which Amgen said helps identify patients who would benefit from treatment with Vectibix. 

June 29, 2017

The agency has outlined its Orphan Drug Modernization plan, which it said is part of a larger effort called the Medical Innovation Development plan modernize and make efficient the FDA’s regulatory tools and policies.

June 29, 2017

The drug had combined sales of $188 million for the 12 months ended April 2017, the company said.

June 26, 2017

Rituxan Hycela contains hyaluronidase human, an enzyme that helps with the subcutaneous delivery of Rituxan's active ingredient, rituximab, allowing for faster administration compared with intravenous Rituxan.

June 23, 2017

US Bioservices has been around for more than 20 years, offering support and dispensing services for patients who need specialty medications.

June 19, 2017

Testing will be available at more than 220 participating Walgreens stores in 130 cities.

June 13, 2017
The Supreme Court has overturned an appeals court decision which said Sandoz had to wait 180 days under federal law after receiving Food and Drug Administration approval to launch its biosimilar of Amgen’s Neupogen (filgrastim), Zarxio (filgrastim-sndz). 
June 12, 2017

The latest report on generics cost savings, compiled by the QuintilesIMS Institute on behalf of the Association for Accessible Medicines, highlights the key role generics play in healthcare cost savings. 

June 9, 2017

Jeff Park was OptumRx’s COO from July 2015 to July 2016 following the company’s merger with Catamaran, where Park had been EVP operations since March 2014.

June 9, 2017

According to the QuintilesIMS Institute’s 2017 Medicine Use and Spending report, Truvada had $3.1 billion in sales on an invoice price basis in 2016, ranking 17th among the top 20 medicines in the U.S. based on invoice spending.

June 6, 2017

The Cincinnati Enquirer included Diplomat Specialty Infusion Group as one of its Top Workplaces 2017. 

June 1, 2017

Since 2011, 68 novel therapies have been approved globally across 22 cancer indications. The QunitilesIMS Institute report looks at what technological advances and development trends have made this possible, as well as their cost.

May 31, 2017

Under the acquisition, MedCart will continue to operate as it did before, but as a new business unit under Albertsons’ pharmacy team structure, with the leadership team reporting directly to Albertsons group VP pharmacy operations, Dain Rusik.

May 30, 2017
India-based Cipla announced May 25 that it would be cutting its investment in its biosimilars development arm to focus on respiratory products, Reuters reported. The company has halted plans to invest $1.3 billion in building a biotechnology plant in South Africa and is on the lookout to partner with other companies on its already existing biosimilars efforts, the report said. "We are not moving away from biosimilars. However, we are not in the aim to make them at $1 a day,” Cipla CEO Umang Vohra said. (Reuters)
May 26, 2017

 Diplomat Pharmacy will be dispensing a recently approved treatment for rheumatoid arthritis.

May 25, 2017

Asembia’s Asembia1 specialty pharmacy workflow platform will be integrated with QS/1’s software platform as a result of the partnership.